Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients

Journal of Trace Elements in Medicine and Biology

Volumn 24, Issue 1, 2010, Pages 27-30

  Taccone Gallucci, Massimo ^a   Noce, Annalisa ^a   Bertucci, Pierfrancesco ^a   Fabbri, Claudia ^a   Manca di Villahermosa, Simone ^a   Della Rovere, Francesca Romana ^a   De Francesco, Marianna ^a   Lonzi, Maurizio ^a   Federici, Giorgio ^a   Scaccia, Franco ^b   Dessì, Mariarita ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Section of Nephrology Umberto I   (Italy)

Author keywords

Hemodialysis; Oxidative stress; Selenium; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SELENIUM; SIMVASTATIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; SELENIUM; UREMIA;

EID: 73449108365     PISSN: 0946672X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtemb.2009.06.005     Document Type: Article

References (32)

1. Zachara B.A., Gromadzińska J., Wa{ogonek}sowicz W., and Zbróg Z. Red blood cell and plasma lutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochem Polon 53 (2006) 663-667
2. Wratten M.L., Tetta C., Ursini F., and Sevanian A.l. Oxidative stress in hemodialysis: prevention and treatment strategies. Kidney Int 76 (2000) S126-S132
3. Rikitake Y., Kawashima S., Takeshita S., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
4. Wassmann S., Laufs U., Muller K., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Atheroscler Thromb Vasc Biol 22 (2002) 300-305
5. Cockroft D., and Gault M.K. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
6. Becker B., Himmelefarb J., Henrich W., and Hakim R.M. Reassessing the cardiac risk profile in chronic haemodialysis patients: a hypothesis on role oxidant stress and other non traditional cardiac risk factors. J Am Soc Nephrol 8 (1997) 475-486
7. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., and Zoccali C. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 18 (2003) 1716-1725
8. Holben O.H., and Smith A.M. The diverse role of selenium within selenoproteins: a review. J Am Diet Assoc 99 (1999) 836-843
9. Ardalan M.R., Tubbs R.S., and Shoja M.M. Vitamin E and selenium co-supplementation attenuates oxidative stress in hemodialysis patients receiving intradialysis iron infusion. Nephrol Dial Transplant 22 (2007) 973-975
10. Richard M.J., Arnaud J., Jurkovitz C., et al. Trace elements and lipid peroxidation abnormalities patients with chronic renal failure. Nephron 57 (1991) 10-15
11. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., and Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 179 (1973) 588-590
12. Yanur O., Bicik Z., Cinar Y., Guney Y., and Guler S. The effect of different dialysis membranes on oxidative stress and selenium status. Clin Chim Acta 346 (2004) 153-160
13. Scandinavian simvastatin survival study investigators. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;334:1383-9.
14. Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with Simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial Lancet 2002;360:7-22.
15. Aronow H.D., Topol E.J., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357 (2001) 1063-1068
16. Ferrieres J., Cambou J.P., Cantet C., and Guize L. Prognosis at six months for coronary and cerebrovascular patients: impact of antiplatelet agents and statins: results from the prevenir III study. Cardiovasc Drugs 20 (2006) 55-61
17. Chan A.W., Bhatt D.L., Chew D.P., et al. Early and substained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105 (2002) 691-696
18. McGirt M.J., Perler B., Brooke B.S., et al. Hydroxy-3-methylglutraryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endartectomy. J Vasc Surg 42 (2005) 829-836
19. Yasuda H., Yuen P., Hu X., Zhou H., and Star R.A. Simvastatin improves sepsis induced mortality and acute kidney injury via renal vascular effects. Kidney Int 69 (2006) 1535-1542
20. Taccone-Gallucci M., Manca di Villahermosa S., Tedesco M., et al. Aggressive medical management in asymptomatic hemodialysis patients: cardiovascular outcome during a three-year follow-up (Abs.). J Am Soc Nephrol 18 (2007) 991A
21. Sukhova G.K., Williams J.K., and Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Atheroscler Thromb Vasc Biol 22 (2002) 1452-1458
22. Nachtigal P., Pospisilova N., Jamborova G., et al. Atorvastatin has hypolipidemic and anti-inflammatory effects in apo-E/LDL receptor double-knockout mice. Life Sci 82 (2008) 708-717
23. Ferms G.A.A. Differential effects of statins on serum CRP levels: implications of recent clinical trials. Atherosclerosis 169 (2003) 349-352
24. Nahrendorf M., Sosnovik D., Chen J.W., et al. Activatable magnetic resonance imaging agents reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 117 (2008) 1153-1160
25. Pizzi C., Manfrini O., Fontana F., and Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxi-3-methylglutaryl coenzyme A reductase in cardiac syndrome X. Role of superoxide dismutase activity. Circulation 109 (2004) 53-58
26. Oranje W.A., Sels J.P., Rondars-Golberg S.J., Lemmens P.J., and Wolffenbuttel B.H. Effect of atorvastatin on LDL-oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 311 (2001) 91-94
27. Ghayour-Mobarhan M., Lamb D.J., Taylor A., et al. Effect of statin therapy on serum trace element status in dyslipidemic subjects. J Trace Elem Med Biol 19 (2005) 61-67
28. Zachara B.A., Salak A., Koterska D., Manitius I., and Wasowicz W. Selenium and glutathione peroxidases in blood of patients with different stage of chronic renal failure. J Trace Elem Med Biol 17 (2004) 291-299
29. Bonomini M., and Albertazzi A. Selenium in uremia. Artif Organs 19 (1995) 443-448
30. Bonomini M., Manfrini V., Marini A., et al. Hemodialysis with regenerated cellulosic membranes does not reduce plasma selenium level in chronic uremic patients. Artif Organs 19 (1995) 81-85
31. Maccarrone M., Meloni C., Manca di Villahermosa S., et al. Vitamin E suppresses 5-lipoxigenase mediated oxidative stress in peripheral blood mononuclear cells of haemodialysis patients regardless of administration route. Am J Kidney Dis 37 (2001) 964-969
32. Taccone-Gallucci M., Manca di Villahermosa S., Battistini L., Giacominelli-Stuffler R., Tedesco M., and Maccarrone M. N3-PUFAs reduce oxidative stress in ESRD patients on maintenance hemodialysis by inhibiting 5-lipoxigenase activity. Kidney Int 69 (2006) 1450-1454